MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318964 | Name: Udenafil
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Udenafil is an inhibitor of phosphodiesterase 5 (PDE5). In vivo, udenafil increases lung cGMP levels, attenuates the development of compensatory right ventricular hypertrophy, and reduces pulmonary arterial wall thickening. It increases creatine clearance and decreases blood urea nitrogen (BUN) and serum malondialdehyde (MDA) levels in a rat model of renal ischemia-reperfusion injury. Udenafil also induces penile erections in conscious rabbits and in rabbits with acute spinal cord injury.

Chemical Structure

Udenafil
Udenafil
CAS#268203-93-6

Theoretical Analysis

MedKoo Cat#: 318964

Name: Udenafil

CAS#: 268203-93-6

Chemical Formula: C25H36N6O4S

Exact Mass: 516.2519

Molecular Weight: 516.66

Elemental Analysis: C, 58.12; H, 7.02; N, 16.27; O, 12.39; S, 6.21

Price and Availability

Size Price Availability Quantity
10mg USD 250.00 2 Weeks
25mg USD 450.00 2 Weeks
100mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
DA-8159, DA 8159, DA8159, Udenafil, Zydena
IUPAC/Chemical Name
3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
InChi Key
IYFNEFQTYQPVOC-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)
SMILES Code
O=S(C1=CC=C(OCCC)C(C(NC2=C3N(C)N=C2CCC)=NC3=O)=C1)(NCCC4N(C)CCC4)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 516.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Amdani S, Shezad MF, Kroslowitz B, Townsend M, Joong A, Najm H, Marino BS, Rosenthal DN, Lorts A, O'Connor MJ. Outcomes for Children With Congenital Heart Disease Undergoing Ventricular Assist Device Implantation: An ACTION Registry Analysis. J Am Coll Cardiol. 2024 Dec 19:S0735-1097(24)10047-2. doi: 10.1016/j.jacc.2024.10.083. Epub ahead of print. PMID: 39772369. 2: Rasheed A, Aslam S, Sadiq HZ, Ali S, Syed R, Panjiyar BK. New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review. Cureus. 2024 Aug 29;16(8):e68117. doi: 10.7759/cureus.68117. PMID: 39347150; PMCID: PMC11438555. 3: Ismail EA, El-Sakka AI. An overview of conventional and investigational phosphodiesterase 5 inhibitors for treating erectile dysfunction and other conditions. Expert Opin Investig Drugs. 2024 Sep;33(9):925-938. doi: 10.1080/13543784.2024.2388569. Epub 2024 Aug 11. PMID: 39096237. 4: Albakr A, El Ansari W, Mahdi M, Megahed H, Lock M, Arafa M, Hothi HA, Ghafouri A. Postmicturition dribble in men with no previous urogenital surgery: Systematic review and meta-analysis of treatment modalities. Neurourol Urodyn. 2024 Sep;43(7):1686-1698. doi: 10.1002/nau.25337. Epub 2023 Nov 30. PMID: 38032134. 5: Edelson JB, Zak V, Goldberg D, Fleming G, Mackie AS, Patel JK, Files M, Downing T, Richmond M, Acheampong B, Cartoski M, Detterich J, McCrindle B, McHugh K, Hansen JE, Wagner J, Maria MD, Weingarten A, Nowlen T, Yoon JK, Kim GB, Williams R, Whitehill R, Kirkpatrick E, Yin S, Ermis P, Lubert AM, Stylianou M, Freemon D, Hu C, Garuba OD, Frommelt P, Goldstein BH, Paridon S, Garg R; Pediatric Heart Network Investigators. The Effect of Udenafil on Heart Rate and Blood Pressure in Adolescents With the Fontan Circulation. Am J Cardiol. 2024 Jan 1;210:183-187. doi: 10.1016/j.amjcard.2023.09.115. Epub 2023 Oct 31. PMID: 37918818; PMCID: PMC10872492. 6: Melchiode Z, Nguyen T, Dawood O, Bobo GA, Hellstrom WJG. Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments. Expert Opin Investig Drugs. 2023 Jul-Dec;32(7):635-642. doi: 10.1080/13543784.2023.2242768. Epub 2023 Aug 1. PMID: 37507822. 7: Goldberg DJ, Hu C, Lubert AM, Rathod RH, Penny DJ, Petit CJ, Schumacher KR, Ginde S, Williams RV, Yoon JK, Kim GB, Nowlen TT, DiMaria MV, Frischhertz BP, Wagner JB, McHugh KE, McCrindle BW, Cartoski MJ, Detterich JA, Yetman AT, John AS, Richmond ME, Yung D, Payne RM, Mackie AS, Davis CK, Shahanavaz S, Hill KD, Almaguer M, Zak V, McBride MG, Goldstein BH, Pearson GD, Paridon SM; Pediatric Heart Network Investigators. The Fontan Udenafil Exercise Longitudinal Trial: Subgroup Analysis. Pediatr Cardiol. 2023 Dec;44(8):1691-1701. doi: 10.1007/s00246-023-03204-y. Epub 2023 Jun 29. PMID: 37382636. 8: Wang Q, Shin BS, Oh SY, Shin YS, Na DL, Kim KW. A pilot study to explore the effect of udenafil on cerebral hemodynamics in older adults. Ann Clin Transl Neurol. 2023 Jun;10(6):933-943. doi: 10.1002/acn3.51774. Epub 2023 Apr 4. PMID: 37013976; PMCID: PMC10270257. 9: Di Maria MV, Goldberg DJ, Zak V, Hu C, Lubert AM, Dragulescu A, Mackie AS, McCrary A, Weingarten A, Parthiban A, Goot B, Goldstein BH, Taylor C, Lindblade C, Petit CJ, Spurney C, Harrild DM, Urbina EM, Schuchardt E, Beom Kim G, Kyoung Yoon J, Colombo JN, Files MD, Schoessling M, Ermis P, Wong PC, Garg R, Swanson SK, Menon SC, Srivastava S, Thorsson T, Johnson TR, Krishnan US, Paridon SM, Frommelt PC; Pediatric Heart Network. Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants. Circ Cardiovasc Imaging. 2022 Nov;15(11):e013676. doi: 10.1161/CIRCIMAGING.121.013676. Epub 2022 Nov 15. PMID: 36378780; PMCID: PMC9674374. 10: Chung JH, Kwon TG, Kwak C, Sung GT, Kim SD, Cho JS, Kim HJ, Ahn H, Jeon SS. Efficacy and Safety of Udenafil Once Daily in Patients with Erectile Dysfunction after Bilateral Nerve-Sparing Robot-Assisted Laparoscopic Radical Prostatectomy: A Randomized, Double-Blind, Placebo-Controlled Study. World J Mens Health. 2023 Jul;41(3):612-622. doi: 10.5534/wjmh.220057. Epub 2022 Sep 2. PMID: 36102102; PMCID: PMC10307658. 11: Song M, Wu Q, Liu B, Li P, Jiang L, Wang Y, Dong S, Xiong Y, Hammock BD, Zhang C. Using a quantum dot bead-based lateral flow immunoassay to broadly detect the adulteration of PDE-5 inhibitors in functional foods. Anal Methods. 2022 Jul 7;14(26):2586-2595. doi: 10.1039/d2ay00580h. PMID: 35723455; PMCID: PMC11257028. 12: Karna KK, Choi BR, Kim CY, Kim HK, Park JK. Rubus occidentalis and Ellagic Acid Affect the Contractility of Penile Corpus Cavernosum Smooth Muscle through the Nitric Oxide-Cyclic Guanosine Monophosphate and Cyclic Adenosine 3',5'-Monophosphate Signaling Pathway. J Clin Med. 2022 May 23;11(10):2947. doi: 10.3390/jcm11102947. PMID: 35629073; PMCID: PMC9148017. 13: Xu H, Zhang S, DU R, Zhou J, Weng S. [Ultra-high performance liquid chromatography-orbitrap high-resolution mass spectrometry for rapid screening and identification of 32 illegally added drugs in slimming and anti-impotence health foods]. Se Pu. 2022 Jun;40(6):531-540. Chinese. doi: 10.3724/SP.J.1123.2021.12009. PMID: 35616198; PMCID: PMC9404125. 14: Rychik J, Goldberg DJ, Rand E, Mancilla EE, Heimall J, Seivert N, Campbell D, O'Malley S, Dodds KM. A Path FORWARD: Development of a Comprehensive Multidisciplinary Clinic to Create Health and Wellness for the Child and Adolescent with a Fontan Circulation. Pediatr Cardiol. 2022 Aug;43(6):1175-1192. doi: 10.1007/s00246-022-02930-z. Epub 2022 May 23. Erratum in: Pediatr Cardiol. 2022 Oct;43(7):1678. doi: 10.1007/s00246-022-02952-7. PMID: 35604474; PMCID: PMC9125546. 15: Alshehri YM, Al-Majed AA, Attwa MW, Bakheit AH. Lodenafil. Profiles Drug Subst Excip Relat Methodol. 2022;47:113-147. doi: 10.1016/bs.podrm.2021.10.004. Epub 2021 Dec 7. PMID: 35396013. 16: Ural A, Bilgen F, Altıntaş Aykan D, Koçarslan S, Altıntaş Ural D, Seyithanoğlu M, Bekerecioğlu M. The Effect of Udenafil on Stasis Zone in an Experimental Burn Model. Ann Plast Surg. 2022 Jan 1;88(1):38-43. doi: 10.1097/SAP.0000000000003045. PMID: 34928244. 17: de Souza Madeira CR, Millan Fachi M, Concentino V, de Fátima Cobre A, Leal Badaró Trindade AC, Gonçalves AG, Pontarolo R. A validated LC-MS/MS assay for the quantification of phosphodiesterase-5 inhibitors in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Aug 1;1179:122829. doi: 10.1016/j.jchromb.2021.122829. Epub 2021 Jun 12. PMID: 34147872. 18: Shodmonova ZR, Gafarov RR, Allazov SA, Giyasov SI. [Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction]. Urologiia. 2021 May;(2):135-140. Russian. PMID: 33960173. 19: Yu HM, Chung HK, Park KS. The PDE5 inhibitor udenafil ameliorates nonalcoholic fatty liver disease by improving mitochondrial function. Biochem Biophys Res Commun. 2021 Jun 18;558:57-63. doi: 10.1016/j.bbrc.2021.04.038. Epub 2021 Apr 22. PMID: 33895552. 20: Dong L, Zhang X, Yan X, Shen Y, Li Y, Yu X. Effect of Phosphodiesterase-5 Inhibitors on the Treatment of Male Infertility: A Systematic Review and Meta- Analysis. World J Mens Health. 2021 Oct;39(4):776-796. doi: 10.5534/wjmh.200155. Epub 2021 Feb 24. PMID: 33663030; PMCID: PMC8443990.

View History

Udonitrectag Lysine

Udonitrectag Lysine